ATE347896T1 - Zusammensetzungen und methoden zur verbesserung der kardiovaskulären funktion - Google Patents

Zusammensetzungen und methoden zur verbesserung der kardiovaskulären funktion

Info

Publication number
ATE347896T1
ATE347896T1 AT01956170T AT01956170T ATE347896T1 AT E347896 T1 ATE347896 T1 AT E347896T1 AT 01956170 T AT01956170 T AT 01956170T AT 01956170 T AT01956170 T AT 01956170T AT E347896 T1 ATE347896 T1 AT E347896T1
Authority
AT
Austria
Prior art keywords
compositions
methods
vitamins
cardiovascular function
improving cardiovascular
Prior art date
Application number
AT01956170T
Other languages
English (en)
Inventor
Terri L Butler
Cyr John St
Clarence A Johnson
Original Assignee
Bioenergy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/677,639 external-priority patent/US6429198B1/en
Application filed by Bioenergy Inc filed Critical Bioenergy Inc
Application granted granted Critical
Publication of ATE347896T1 publication Critical patent/ATE347896T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01956170T 2000-07-28 2001-07-27 Zusammensetzungen und methoden zur verbesserung der kardiovaskulären funktion ATE347896T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22152600P 2000-07-28 2000-07-28
US09/677,639 US6429198B1 (en) 1999-04-12 2000-10-03 Compositions for increasing athletic performance in mammals
US30220001P 2001-06-29 2001-06-29

Publications (1)

Publication Number Publication Date
ATE347896T1 true ATE347896T1 (de) 2007-01-15

Family

ID=27396950

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01956170T ATE347896T1 (de) 2000-07-28 2001-07-27 Zusammensetzungen und methoden zur verbesserung der kardiovaskulären funktion

Country Status (8)

Country Link
EP (1) EP1313488B1 (de)
JP (1) JP2004505056A (de)
CN (1) CN1299690C (de)
AT (1) ATE347896T1 (de)
AU (1) AU2001278197A1 (de)
DE (1) DE60125191T2 (de)
ES (1) ES2275703T3 (de)
WO (1) WO2002009727A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003257591A1 (en) * 2002-08-30 2004-03-19 Mitsubishi Pharma Corporation Preventive and/or therapeutic agent for heart failure
JP5065570B2 (ja) * 2002-09-06 2012-11-07 第一三共ヘルスケア株式会社 血管内皮性酸化窒素の合成促進剤
JP2007106703A (ja) * 2005-10-14 2007-04-26 Nutri Kk 血管障害の予防および治療組成物
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
WO2007129618A1 (ja) * 2006-05-08 2007-11-15 National University Corporation Kagawa University 好中球の活性化および遊走因子の抑制剤およびその利用
US8835396B2 (en) * 2006-12-15 2014-09-16 Bioenergy, Inc. Method and compositions for improving pulmonary hypertension
AU2008322437B2 (en) * 2007-11-15 2013-11-07 Louisiana State University Use of nitrite salts in chronic ischemia
US8710018B2 (en) * 2008-01-25 2014-04-29 John E. Foker Methods and compositions for inhibiting progression to chronic cardiac failure
CN106138071A (zh) * 2008-04-02 2016-11-23 生物能公司 核糖在对于急性心肌梗塞的第一反应中的用途
IT1391588B1 (it) * 2008-10-15 2012-01-11 Giellepi Chemicals S P A Composizione sinergica per il recupero e la riduzione del danno ischemico lieve
GB201223365D0 (en) * 2012-12-24 2013-02-06 Provexis Natural Products Ltd Compositions
KR101666907B1 (ko) * 2014-12-16 2016-10-18 변종현 변성 타우린 및 이를 포함하는 대사질환 예방 또는 치료용 약학조성물
KR101666913B1 (ko) * 2014-12-23 2016-10-17 변종현 당 및 타우린을 포함하는 대사질환 예방 또는 치료용 약학조성물
CN109998101A (zh) * 2019-01-28 2019-07-12 天津星宇航天生物科技有限公司 一种适用心脏调养人群的宇航民用营养配方
CN110664824B (zh) * 2019-08-09 2021-01-01 北京佳博泰和健康科技有限公司 一种营养支持剂及其制备方法和用途
CN114209709A (zh) * 2021-12-16 2022-03-22 海门品尚医药科技有限公司 D-核糖在制备改善药物性心脏毒性药物或食品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871718A (en) * 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
JPH02286620A (ja) * 1989-04-27 1990-11-26 Riide Chem Kk 抗高脂血症用剤
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
US5707971A (en) * 1995-06-07 1998-01-13 Life Resuscitation Technologies, Inc. Modulation of glycolytic ATP production
US6218366B1 (en) * 1998-06-19 2001-04-17 Bioenergy, Inc. Method for raising the hypoxic threshold
US6159942A (en) * 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
US6420342B1 (en) * 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof

Also Published As

Publication number Publication date
JP2004505056A (ja) 2004-02-19
DE60125191T2 (de) 2007-10-25
ES2275703T3 (es) 2007-06-16
EP1313488A1 (de) 2003-05-28
EP1313488A4 (de) 2005-11-30
EP1313488B1 (de) 2006-12-13
CN1454090A (zh) 2003-11-05
DE60125191D1 (de) 2007-01-25
WO2002009727A1 (en) 2002-02-07
CN1299690C (zh) 2007-02-14
AU2001278197A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
DE60125191D1 (de) Zusammensetzungen und methoden zur verbesserung der kardiovaskulären funktion
EP2769715A3 (de) Verfahren zur Behandlung von Autoimmunkrankheiten und damit zusammenhängende Reagenzien
BR0315169A (pt) Referência cruzada a pedidos de patente relacionados
CY1108342T1 (el) Ανοσορρυθμιστικοι ολιγοσακχαριτες
IL186788A0 (en) Nutritional supplement for hiv patients
MX2007008021A (es) Composiciones que incluyen hierro.
WO2003038123A3 (en) Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
ATE293974T1 (de) Pharmazeutische zusammensetzungen zur unbehagenverminderung
WO2005017192A3 (en) Screening for gestational disorders
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
WO2005058961A3 (en) Antibodies specific for human galanin, and uses thereof
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
EP1505990A4 (de) Verfahren zur behandlung von hepatitis
PT1411960E (pt) Produto alimentar enriquecido a base de farelo de arroz para promocao da saude cardiovascular
ATE329601T1 (de) Medizinische zusammensetzungen zur behandlung oder vorbeugung eines funktionellen vitamin b12 mangels
EP2241196A3 (de) Oligosaccharide und Zysteine enthaltendes Nahrungsergänzungsmittel zur behandlung von hiv
MXPA05012074A (es) Procesos y composiciones para la elaboracion de leche saborizada.
TNSN05065A1 (en) Use of prebiotics for the treatment and prevention of hyperglycaemic syndromes
BRPI0413618A (pt) xarope multivitamìnico para crianças ou adolescentes
WO2000057721A3 (en) Edible solids for treatment of glucose metabolism disorders
SI1708711T1 (sl) Spojine uporabne posebno za zdravljenje ali prepreäśevanje metaboliäśnega sindroma
WO1999058098A3 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
PL1838716T3 (pl) Dihydrat embonianu olanzapiny

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1313488

Country of ref document: EP